CBIO CRESCENT BIOPHARMA

Health Care · Russell 2000

Next earnings: not announced yet

What 9 analyst firms say about CRESCENT BIOPHARMA: their latest ratings, price targets and how far the stock is from them. How it works

13.54 USD+0.60 (+4.64%) today

Price as of 6 Nov 16:00 ET

Analyst window: Latest analyst report within last 6 months

Analyst view · last 6M

+149.6%to the avg target 33.80 USD+20.26 USD

Buy 7 · Hold 1 · Sell 0

8 rated views · 9 analyst/firm records · 9 firms

Latest report19 Oct 2026avg report date 4 Sep

Target rangePrice is below every target

now 13.54

Radar score

Russell 2000 · Top Picks · 6MGood · #64 in the index84
Russell 2000 · Safest consensus · 6MBelow the Radar threshold of 8057

Recent analyst activity · last 90 days

Our tracked history has 6 reports on CBIO from 4 analyst firms in the last 90 days (12 firms in the past year).

Comparing each firm's latest target with its previous one: 2 left it unchanged and 1 has its first observed target in the past year.

No firm's latest available rating differs from its previous one.

Latest observed target change: HC Wainwright raised its target from $22.00 (set 2 Mar 2026) to $36.00 on 6 Oct 2026.

Last 6 months. Latest opinion per identifiable analyst within the last 6 months. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.

Firm	Analyst	Latest rating	Report date	Latest target (USD)
Cantor Fitzgerald	Eric Schmidt	Buy	15 Jun 2026	—
H.C. Wainwright	Mitchell S. Kapoor	Buy	19 Oct 2026	36.00 USD
Jefferies	Akash Tewari	Buy	1 Jul 2026	35.00 USD
Piper Sandler	Biren Amin	Buy	30 Jul 2026	35.00 USD
TD Cowen	Tyler Van Buren	Buy	24 Aug 2026	—
UBS	Unnamed analyst	Buy	19 Oct 2026	36.00 USD
Wedbush	Robert Driscoll	Buy	14 Sep 2026	27.00 USD
Weiss Ratings	Unnamed analyst	—	7 Aug 2026	—
Data feed RESEARCH	Research Team	Hold	15 Jun 2026	—

Partial coverage · checked 6 Nov (6 Nov 2026, 07:01 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.